Base Year
Historical Year
Forecast Year
The global focal segmental glomerulosclerosis (FSGS) treatment market attained a value of USD 23.60 billion in 2023. The market is expected to grow further at a CAGR of 8.3% during the forecast period of 2024-2032 to attain a value of 48.17 billion by 2032, driven by the rising prevalence of the diabetes and other kidney disorders.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Focal segmental glomerulosclerosis is a serious kidney disorder which can lead to kidney failure. In this disease, a scar tissue gets developed in the small parts of the kidneys, known as glomeruli, that filter waste from the blood. It can be caused due to various factors including diabetes, obesity, sickle cell disease, infection, drug toxicity, inherited abnormal genes, or any other kidney ailments.
The condition can be of different types and the treatment pathway significantly depends on the type of the disease. The different types of focal segmental glomerulosclerosis (FSGS) include the following:
Primary FSGS- This type of FSGA happens when the exact cause remains unknown, the source remains unknown.
Secondary FSGS- The secondary type might be caused due to consumption of some drug or due to another disease. The causes can include various factors like drug toxicity, diabetes, infection, sickle cell disease, other kidney ailments. Targeting these underlying causes can lead to the slow progression of kidney damage and might heal the functioning of the kidney over time.
There is one more type, known as the genetic FSGS, which is the rare form of the disease and also referred to as familial FSGS. This type of FSGS is usually caused due to genetic factors. However, it can happen to people whose parents are not affected but might be carrying a copy of an altered gene, which can unknowingly be passed on to the next generations.
Common symptoms of focal segmental glomerulosclerosis (FSGS) include the following:
In some cases, FSGS can also cause nephrotic syndrome where the above mentioned symptoms, along with some additional symptoms, can show up altogether and can severely affect the kidneys. If the condition advances further, the patient might experience symptoms like fatigue, nausea, shortness of breath, poor appetite, headache, and itchy skin.
FSGS can be diagnosed with a blood test, urine test, and a kidney biopsy.
Urine Test: A urine test will help find protein and blood in your urine.
Blood Test: A blood test will help find levels of protein, cholesterol, and wastes in your blood.
Glomerular Filtration Rate (GFR): A blood test will be done to know how well your kidneys are filtering the wastes from your body.
Kidney Biopsy: In this test, a tiny piece of your kidney is removed with a special needle and looked at under a microscope.
Genetic Testing: A genetic test may be done to see if you were born with genes that caused your kidney disease. This information may help your doctor decide what type of treatment is best for you.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The focal segmental glomerulosclerosis (FSGS) treatment market can be categorised into disease type, diagnostic method, treatment method, treatment channel, and region.
Market Breakup by Disease Type
Market Breakup by Diagnosis Method
Market Breakup by Treatment Method
Market Breakup by Treatment Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The condition is more prevalent in people of all ages but affects males more than females. In terms of race, the disease is most likely to happen to African Americans.
The treatment pathway can be of the following types and depends on the kinds of symptoms:
Medications- These are used to control the symptoms in order to limit the progression of FSGS and control it as much as possible. The most common medicines used in the treatment of FSGS include angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB) medication, cyclosporine, and prednisone, among others.
Dialysis- There are two types of dialysis that help in the normal functioning of the kidney, haemodialysis and peritoneal dialysis. Dialysis helps your body remove wastes and toxins from the body when the kidney becomes unable to.
Kidney Transplant- Transplant is the preferred method of treatment when the kidney of a person is barely working or stops working completely. A healthy kidney, either from a living person or a deceased person, is transplanted in the patient to enable the functioning of the kidney.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Diagnosis Method |
|
| Breakup by Treatment Method |
|
| Breakup by Treatment Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The focal segmental glomerulosclerosis (FSGS) treatment market attained a value of USD 23.60 billion in 2023.
The market is projected to grow at a CAGR of 8.3% during the forecast period of 2024-2032.
The market is estimated to witness healthy growth during the forecast period of 2024-2032 to reach a value of USD 48.17 billion by 2032.
The growth of the market is driven by factors like rising prevalence of kidney disorders.
The key trends in the market include the rising support of the government in kidney treatments.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The disease types include primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis.
The diagnostic methods include kidney function testing, kidney imaging, and kidney biopsy.
Treatment methods can be classified into medication, dialysis, and kidney transplant.
Treatment channels can be categorised into public and private channels.
The major players in the market are Variant Pharmaceuticals, Inc., Inc., Sanofi S.A., Pfizer Inc., GlaxoSmithKline Plc., Aurinia Pharmaceuticals Inc., Medtronic Plc., B. Braun Melsungen AG, Bristol-Myers Squibb Co., Reata Pharmaceuticals Inc., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc., and Travere Therapeutics.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share